21 Invest, a European investment group established in Italy in 1992, has launched its first fund dedicated to the healthcare sector. The fund has successfully closed its initial fundraising round at €70 million, with a target of reaching €150 million.

This move is significant for 21 Invest, which focuses on mid-market companies. The new fund follows an impact investment strategy and is classified under Article 9 of the European Sustainable Finance Disclosure Regulation (SFDR).

In addition, 21 Invest recently acquired a majority stake in Rocamed SAM, a French medtech company specializing in endo-urological medical devices, further demonstrating its commitment to the healthcare industry.